Harold Burstein, MD, PhD, and Sarah Sammons, MD, discuss the DESTINYBreast09, HER2-CLIMB, and PATINA CNS trials for first-line treatment in advanced breast cancer, which were presented at the 2025 San Antonio Breast Cancer Symposium.
Published
March 17, 2026
Created by
Related Presenters
